NEUROLOGY DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Neurology Drugs Market, By Disease Type (Alzheimer’s Disease, Parkinson’s Disease, Epilepsy, Multiple Sclerosis, Migraine, Huntington’s Disease, and Others), By Drug Class (Antiepileptics, Antipsychotics, Dopamine Agonists, Cholinesterase Inhibitors, NMDA Receptor Antagonists, Analgesics (Migraine-specific), and Others), By Route of Administration (Oral, Injectable, and Transdermal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)

Published In: 03 Apr, 2026
Code: CMI9418
Page number: 152
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range : 2020 - 2024
- Base Year : 2025
- Estimated Year : 2026
- Forecast Period : 2026 - 2033

The global neurology drugs market is estimated to be valued at USD 74 Bn in 2026 and is expected to reach USD 104 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 4.98% from 2026 to 2033. The global neurology drugs market is an important segment of the pharmaceutical industry, and its scope is to address complex diseases affecting the central and peripheral nervous systems.

Neurology drugs include treatments for various diseases, such as epilepsy, Alzheimer's, Parkinson's, multiple sclerosis, migraine, stroke, and many more. The growth of the neurology drugs market is mainly propelled by an increase in the prevalence of neurological disorders, rising aging population, and an increased understanding of neurobiological mechanisms. The increased prevalence of neurological diseases, particularly in developed and emerging countries, is a key driver of the growth of the neurology drugs market.

On the other hand, there are increased R&D activities by companies to introduce new therapies such as drug delivery systems, personalization of medicine, and new therapies for different conditions. The market is highly regulated, with clinical validation due to a complex risk profile associated with therapies for neurological conditions. Major factors such as patent expiration, generics, changes in healthcare infrastructure, and changes in clinical guidelines are other key drivers for this market. Furthermore, gene therapy, immunotherapy, and precision medicine are changing the current therapy landscape, thus providing new opportunities for the management of this condition.

Market Dynamics

The global neurology drugs market is fueled by various factors related to demography, technology, and healthcare. Growing cases of dementia, Parkinson’s disease, and epilepsy among the aging population contribute to the growth of the neurology drugs market. Improvements in drug discovery techniques, including the application of artificial intelligence in drug discovery, the identification of biomarkers, and the application of precision medicine, further propels the growth. Additionally, increasing healthcare expenditure, improvements in diagnostic techniques, and the expansion of the healthcare infrastructure in emerging markets also contribute to the growth of the neurology drugs market.

However, there are certain challenges in this market, which include high R&D costs and regulatory approvals, which act as a restraint in this market for new entrants. The expiration of patents on blockbuster drugs creates a competitive environment in the generics segment, which affects the revenue received by these companies. Challenges in clinical trials, ethical issues, and high failure rates in late-stage drug development are other issues in this market. In addition, there are safety issues and the occurrence of adverse effects, which necessitate surveillance in this market.

Despite the challenges, there are many opportunities in this market, especially in the new markets of developing nations, which are growing in terms of healthcare infrastructure and medical tourism. Orphan drugs for neurological disorders, digital therapeutics, combination therapies, and drug delivery systems are opportunities in this market for future growth.

Key Features of the Study

This report provides in-depth analysis of the global neurology drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neurology drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Merck & Co., Teva Pharmaceutical Industries, Eisai, H. Lundbeck, UCB, Otsuka Pharmaceutical, and Jazz Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global neurology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurology drugs market

Market Segmentation

Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Alzheimer’s Disease
- Parkinson’s Disease
- Epilepsy
- Multiple Sclerosis
- Migraine
- Huntington’s Disease
- Others
Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Antiepileptics
- Antipsychotics
- Dopamine Agonists
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Analgesics (Migraine-specific)
- Others
Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Injectable
- Transdermal
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - North Africa
  - Central Africa
Key Players Insights
- Hoffmann-La Roche
- Johnson & Johnson
- AbbVie
- Merck & Co.
- Teva Pharmaceutical Industries
- Eisai
- Lundbeck
- UCB
- Otsuka Pharmaceutical
- Jazz Pharmaceuticals

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Global Neurology Drugs Market, By Disease Type
  - Global Neurology Drugs Market, By Drug Class
  - Global Neurology Drugs Market, By Route of Administration
  - Global Neurology Drugs Market, By Distribution Channel
  - Global Neurology Drugs Market, By Region
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
Global Neurology Drugs Market, By Disease Type, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Alzheimer’s Disease
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Parkinson’s Disease
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Epilepsy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Multiple Sclerosis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Migraine
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Huntington’s Disease
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Neurology Drugs Market, By Drug Class, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Antiepileptics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Antipsychotics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Dopamine Agonists
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Cholinesterase Inhibitors
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- NMDA Receptor Antagonists
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Analgesics (Migraine-specific)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Neurology Drugs Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Oral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Injectable
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Transdermal
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Neurology Drugs Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Neurology Drugs Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
  - Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
  - Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    - Brazil
    - Argentina
    - Mexico
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    - Germany
    - U.K.
    - Spain
    - France
    - Italy
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    - GCC Countries
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    - South Africa
    - North Africa
    - Central Africa
Competitive Landscape
- Hoffmann-La Roche
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Johnson & Johnson
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AbbVie
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Merck & Co.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Eisai
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Lundbeck
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- UCB
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Otsuka Pharmaceutical
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Jazz Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
References and Research Methodology
- References
- Research Methodology
- About us

*Browse 32 market data tables and 28 figures on 'Neurology Drugs Market' - Global forecast to 2033

Get Instant Access - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now